epirubicin has been researched along with Exanthem in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blohmer, JU; Costa, SD; Eidtmann, H; Fasching, PA; Gerber, B; Hanusch, C; Hilfrich, J; Höß, C; Huober, J; Jackisch, C; Khandan, F; Kittel, K; Krabisch, P; Kümmel, S; Loibl, S; Mau, C; Minckwitz, Gv; Nekljudova, V; Rezai, M; Schwedler, K; Tesch, H; Untch, M | 1 |
| Bell, D; Keefe, DM; Ma, DD; Turtle, CJ; Wheeler, H | 1 |
1 trial(s) available for epirubicin and Exanthem
| Article | Year |
|---|---|
Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Epirubicin; Everolimus; Exanthema; Female; Humans; Mastectomy, Segmental; Middle Aged; Mucositis; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Sirolimus; Thrombocytopenia; Treatment Outcome | 2013 |
1 other study(ies) available for epirubicin and Exanthem
| Article | Year |
|---|---|
Severe adverse reaction to high dose epirubicin and cyclophosphamide for poor prognosis breast cancer.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Edema; Epirubicin; Exanthema; Female; Fever; Humans; Hypotension; Hypoxia; Middle Aged; Prognosis | 1999 |